Objective: Whether to graft a moderately stenosed coronary vessel remains debatable. We investigated whether grafting such vessels is warranted based on angiographic evidence of disease progression.
Recent trials and database analyses of long-term outcomes following coronary revascularization have reinforced the place of coronary artery surgery as the gold standard therapy for multivessel disease. 1 Most patients referred for surgery have severe disease unsuitable or unfavorable for percutaneous intervention. Many of these patients will also have 1 or more moderate lesions, with luminal stenosis estimated around 50%, and surgeons frequently have to decide whether such vessels require bypass grafting. Studies of the assessment of fractional flow reserve in moderate lesions, largely used to guide requirement for placement of coronary stents, have suggested that the majority are not flow limiting in their moderate state, 2 so the decision to graft is based primarily upon anticipation of further progression to greater severity.
The choice that the surgeon must make depends, in essence, on 3 judgments: the likelihood of progressing to severe stenosis or occlusion, the likelihood of the lesion remaining static or regressing, and the outcome (patency) of a graft placed to such a moderate lesion (which in itself depends on the conduit used and location of the target artery). This decision is likely affected by other factors, such as how many other severe lesions require grafting or which other cardiac procedures need to be performed, because containment of the cardiopulmonary bypass or aortic crossclamp time and total operative time may be a priority in practice, and there may not be adequate conduit to bypass every diseased vessel.
Existing data on which the surgeon must make these judgments is conflicting, and much of the data predate modern secondary prevention therapy, such as the widespread use of statin and antiplatelet therapy. In some studies, follow-up angiography may have been prompted by recurrence of symptoms, which may result in a bias and overestimation of the incidence of graft failure or progression of native vessel disease (PNVD).
In an attempt to provide contemporary data to inform this decision, we sought to compare pre-and postoperative angiograms undertaken as part of a randomized trial of arterial and venous conduits, with a program of protocoldriven angiography up to 10 years after surgery, in conjunction with regular surgical and cardiologic follow-up. The fate of moderate lesions in these patients offers some insight that may inform the decision making of the surgeon today.
METHODS
This study derives from the Radial Artery Patency and Clinical Outcomes (RAPCO) trial, the design of which has been published elsewhere. 3 The primary aim of RAPCO is to assess the long-term patency and clinical outcomes of the radial artery, right internal thoracic artery, and saphenous vein when grafted to the largest non-left anterior descending artery target. The RAPCO Trial enrolled a total of 619 patients for coronary bypass surgery using cardiopulmonary bypass, and all patients received the gold standard in situ left internal thoracic artery to the left anterior descending artery.
Patients receive annual telephone and clinical reviews for at least 10 years after surgery. Using a second random assignment, protocoldirected angiograms were allocated at intervals of 1, 2, 5, 7, and 10 years, with the bulk weighted to the second half of the follow-up because this was anticipated to coincide with the majority of graft occlusion events. In addition, elective angiograms at the 5-and 10-year marks were offered to all patients. All angiograms are reported independently by 3 coronary specialists. Graft failure is defined as occlusion,>80% stenosis, or string sign, and is recorded along with any pathologic findings at the proximal or distal anastomoses. Any disputed findings are assessed further by a fourth independent observer. Severity of native vessel disease is assessed similarly by the 3 observers, with the native vessels divided into proximal, mid, and distal sections, and the location and percent stenosis recorded. The latter is recorded in the database as the mean of the 3 estimations. In addition to the percent stenosis, lesions have been ascribed a grade that we have used to group lesions of similar severity or functional significance, because we noted a pattern with which observers consistently classify the same lesions with a particular percentage, depending on whether the lesion is nonflow limiting (grade 0), moderate (grade 1), flow limiting (grade 2), severe or subtotally occlusive (grade 3), and totally occlusive (grade 4). Grade 0 is 0% to 39% stenosis, grade 1 is 40% to 69%, grade 2 is 70% to 80%, grade 3 is 81% to 99%, and grade 4 represents total occlusion. Vessels recorded were the left main stem, left anterior descending and each diagonal branch, circumflex and each obtuse marginal branch, right coronary, posterior descending, and posterolateral branch. Computerized quantitative assessment was not performed as part of the trial, because this was intended to be a pragmatic study replicating real-life practice, in which computerized quantitative assessment is not used widely in Australia.
All patients in RAPCO who have undergone at least 1 postoperative angiogram were included in this study, and each of their coronary artery branches formed a unique data point. By researching the database, the severity of each native vessel lesion was compared in the preoperative and postoperative angiograms (or most recent postoperative angiogram when more than 1 exists), and the duration of imaging follow-up was calculated. Change in severity of the stenosis was recorded together with the presence, type, and patency of any graft to the vessel noted. Change of more than 1 grade, or to occlusion, was defined as PNVD. If a native vessel lesion changed by>1 grade, the angiograms were reviewed to check that the same lesion was being compared. Similarly, any incidence of regression was reviewed.
Statistical analysis was performed using SPSS software (SPSS Statistics 19; IBM Corporation, Somers, NY). Dichotomous variables were analyzed using the Pearson c 2 test, and continuous variables were analyzed using the Student t test. The Cox proportional hazards regression model was used to assess for independent predictors of disease progression. Graft patency was estimated by the Kaplan-Meier method and the log-rank was test used to test for differences between groups.
All patients consented to the surgery, angiograms, annual telephone follow-up, and surgical reviews. The RAPCO protocol was approved by the Austin Hospital Human Research Ethics Committee (project no. H95/086). Further approval was gained for this project as a substudy within RAPCO (December 3, 2008, project no. H2006/02690).
RESULTS
Of the 619 patients originally enrolled in RAPCO, 405 had undergone at least 1 protocol, elective or symptomdirected angiogram, postoperatively. Mean duration of follow-up was 6.17 years (range, 0-14 years). A total of 3816 native coronary artery branches were identified, of which 386 contained at least 1 moderate lesion on the preoperative angiogram (40%-69% stenosis), and 1356 vessels were significantly stenosed (defined as flow limiting or severe stenosis, luminal diameter narrowed by !70%). Patients received 800 arterial grafts and 442 saphenous vein grafts, functionally bypassing a total of 1940 native coronary vessels, as some grafts backfilled more than 1 coronary artery branch. Grafting of undiseased vessels occurred when grafts were placed to healthy distal branches in the presence of isolated proximal disease in the common stem-for example, in isolated left main stem stenosis.
Change in Native Vessel Disease Table 1 shows the likelihood of progression, regression, or stability of a moderate or severe coronary lesion on follow-up angiography. In the overall cohort of native vessels (ranging from no stenosis to complete occlusion preoperatively), rates of progression, regression, and stability were 27.2%, 9.0%, and 63.8%, respectively. Severe lesions (stenosis ! 70%) were at higher risk of progressive atherosclerosis (46.7% vs 36.3%, P<.001) and were less likely to Figure 1 , which pools the right and left circulations and grafted verses ungrafted vessels, and demonstrates the time course of progression. Tables 2 and 3 separate bypassed and nonbypassed vessels according to lesion severity, and left and right coronary circulations. This illustrates a relatively constant prevalence of disease progression on the left side, regardless of moderate or severe stenosis and of the presence or absence of a bypass graft. In the right coronary circulation, however, the prevalence of progression is markedly different between moderate and severe lesions and is influenced strongly by coronary grafting in vessels with moderate stenosis.
Influence of Grafting on Native Vessel Disease
Overall, bypassed native vessels were more likely to exhibit change (Table 2) , with greater risk of disease progression and regression compared with their ungrafted counterparts (43.4% vs 10.5%, P <.001, and 15.2% vs 2.61%, P < .001, respectively). This was true in both the left and right circulations. Correspondingly, native vessels that were not bypassed were more likely to remain unchanged over long-term follow-up, with 86.9% of nonbypassed vessels remaining in status quo compared with 41.4% of bypassed vessels (P<.001). Multivariate analysis (Table 4) confirms that the presence of a bypass graft is an independent predictor for progression of disease in the left and right territories (hazard ratio for disease progression, 3.28 and 6.35, respectively, P <.001 for both).
Stability of Moderate (40%-69%) Lesions
In moderate lesions, the effect of bypassing a vessel on its disease progression appears dependent on target site. Bypassed moderate vessels in the right circulation showed greater progressive disease than their ungrafted counterparts (40.2% vs 13.8%, P ¼ .008) and lesser stability (52.0% vs 75.9%, P ¼ .022). In contrast, bypassing a moderate lesion in the left coronary system did not influence significantly its risk of disease progression (35.7% vs 47.1%, P ¼ .204, for bypassed and nonbypassed moderate left-sided lesions). In the absence of a bypass graft, however, moderate lesions exhibited a different pattern of disease behavior when comparing the left with the right. The right circulation was more stable, with a lower incidence of disease progression (13.8% vs 47.1%, P ¼ .005), and more vessels remaining unchanged (75.9% vs 35.3%, P<.001) than the left (Table 3) .
Development of New Disease
It is notable from Table 2 that when disease-free vessels are bypassed (usually because they lie distal to a more diseased vessel that requires grafting and therefore become a potential meeting point for flow from the native circulation and the bypass conduit), the risk of development of flow-limiting disease in a previously healthy vessel is increased approximately 5-fold compared with ungrafted healthy vessels. And just as for bypassed moderate lesions, the right coronary system seems more vulnerable, with a 17-fold increase in disease development in bypassed undiseased branches (Table 3) .
Patency of Grafts Anastomosed to Moderately Stenosed Native Vessels
Patency of grafts anastomosed to moderately stenosed native vessels is summarized in Figures 2 and 3 . Overall graft survival in the left circulation was 83.2% after 8 years of follow-up. There was a trend to inferior graft patency in the right circulation-73.3% at 7 years (P ¼ .051). Surprisingly, despite being grafted to moderately stenosed vessels, arterial conduits showed excellent patency in the left circulation (83% at 8 years). Comparison with arterial grafts placed to the right circulation is not meaningful because of inadequate numbers (n ¼ 13), but is estimated at 75% at 2 years. Vein grafts show similar patency in the left and right circulations (77% at 8 years and 72% at 7 years, respectively), and numbers are insufficient to detect any difference between them.
Impact on Clinical Outcome of Grafting Moderate Lesions
There was no significant difference in the requirement for subsequent revascularization during follow-up of moderate lesions depending on whether they were grafted not, although there were arguably too few revascularization events for meaningful analysis (Table 5 ). Among moderate left-sided lesions, only 2 grafted vessels and 1 ungrafted vessel required revascularization (P ¼ .31), and among right-sided lesions the incidence was 2 grafted and 2 ungrafted (P ¼ .17). Survival was not affected by grafting or nongrafting of a moderate lesion. Data regarding angina recurrence were not recorded. 
Other Factors Associated With Progression of Native Vessel Disease
Comparison of patients <70 years and !70 years did not show a significant difference in disease progression, although older patients were more like to experience regression of a lesion (Table 6 ). In the multivariate analysis, increasing age was an independent risk factor for progression, together with hypertension and the presence of a graft. This was true for both the left and right circulations ( Table 4) . The use of an arterial graft for a lesion in the right circulation (largely severe) was protective against PNVD, an effect not replicated on the left side.
Multivariate analysis of moderate lesions (Table 4 ) confirms that bypassed moderate lesions in the right coronary system were more likely to progress than their leftsided counterparts (hazard ratio for disease progression, 1.78; P ¼ .041), but nonbypassed moderate vessels were more stable on the right side, with a 77% decreased risk of disease progression on the right (hazard ratio, 0.23; P ¼ .014). The type of bypass conduit did not affect the odds of disease progression in moderately stenosed vessels.
DISCUSSION
The decision to graft or leave a moderately stenosed vessel during a cardiac surgical procedure depends on a number of calculations by the surgeon. In clinical practice, the balance of these estimations of the future of both the lesion and any graft placed to that territory, must be weighed against other surgical considerations, such as the availability of conduit, the number of grafts, and other operative procedures needed, such as valvular or aortic repair. Faced with a moderate lesion, the surgeon might commonly choose between leaving it alone or placing a saphenous vein bypass, given that arterial grafts have been reported to show lower patency as a result of competitive flow in lesions with<70% stenosis. [4] [5] [6] [7] The results presented here offer some contemporary data on which to base this decision, taking into account the potential impact of secondary prevention measures and the influence exerted by grafting. A number of conclusions present themselves: (1) that an ungrafted right-sided moderate lesion is less likely to progress than its left-sided counterpart, and that it has a very low hazard for progression on multivariate analysis, but that the chances of lesion progression are substantially increased if a graft is placed to this territory; and (2) that the patency of an arterial or venous graft to the moderately diseased left-sided target is relatively good at 7 to 8 years, which is possibly superior to that of right-sided grafts to similar lesions (P ¼ .051). There was no correlation with age, despite the attraction of shortening bypass times in elderly patients by avoiding excessive grafting.
From these findings, one might argue in favor of grafting a left-sided moderate lesion with whatever conduit the surgeon prefers, given that the risk of progression is higher and the outcome of the graft is likely to be good, but leaving a right-sided lesion alone, given the low risk of progression if left undisturbed. The limited clinical outcome data do not record angina recurrence, but they do show a low event rate for subsequent revascularization of a moderately stenosed vessel during follow-up after coronary artery bypass grafting (CABG), regardless of whether it is grafted , and from this one might argue in favor of leaving all moderate lesions. However, with angiographic progression seen in almost half of such lesions on the left side, we suggest that these should be best addressed during CABG. Our finding of equivalent patency for arterial and venous grafts placed to such moderate left-sided lesions is surprising, but if correct may widen the scope of conduit availability for the moderately stenosed vessel on this side.
Studies of fractional flow reserve (FFR) suggest that the key question here is not the current impact on flow of a moderate lesion, but rather the likelihood of subsequent progression. For example, in the Deferral of Percutaneous Coronary Intervention (DEFER) study, 2 FFR of moderately stenosed vessels was measured, and evidence of significant flow limitation (ie, ischemia) was shown in a minority of such lesions only. When these were randomized to medical therapy or intervention, the risk of clinical events in medically managed patients was only 1% per annum, and lower than if percutaneous coronary intervention (PCI) was performed for the moderate lesion. It can be argued that the presence of an intracoronary stent for a lesion that is not flow limiting represents a greater risk to the patient, in terms of stent thrombosis and myocardial infarction, than a spurious bypass graft. However, the high incidence of progression of right coronary disease following bypass of moderate right coronary lesions suggests that these grafts may not be harmless either, as increased progressive disease leaves the patient dependent on graft flow for a territory, and the graft may undergo progressive degeneration. Similarly, the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) study randomized participants to percutaneous revascularization guided by physiologic flow reserve or by anatomic stenosis derived by angiography. 8 Primary and composite end points were superior when a functional assessment was used to guide requirement for PCI. Studies such as FAME and DEFER have highlighted that physiologic (flow) data are more important than anatomic stenosis, on which most of the surgical literature is centered.
Ideally, coronary grafting could be directed similarly by pressure or flow data. Yet even if we are able to identify the flow limiting lesions correctly and then bypass them, the best management of the nonflow-limiting moderately stenosed counterpart still depends on the likelihood of progression, and it is here that our data may assist in the clinical decision.
Earlier important studies of PNVD and of the impact of coronary grafting have been published elsewhere, but most of these studies predate modern multifaceted secondary prevention by statins, angiotensin-converting enzyme inhibition, and antiplatelet therapy, with their pleiotropic effects on plaque stabilization, inflammation, lipid accumulation, platelet adhesion, and vascular smooth muscle function. This may account for some differences in our findings, but several similarities persist. Our finding that moderate lesions are more stable than severe lesions was first described 30 years ago in a study showing similar relationships between progression in lesions of lesser or greater severity, even without the significant advances in secondary prevention therapy in the intervening 3 decades. 9 The landmark Coronary Artery Surgery Study (CASS) 10 also divided coronary lesions into grades of severity, and the risk of progression/occlusion was shown to increase with each increase in grade of stenosis, an observation that was replicated by Malinow and colleagues 11 in a smaller study of 100 patients.
Similarly, the observation that bypassing a coronary artery increases significantly its risk of disease progression or development of new lesions has been reported elsewhere. [9] [10] [11] [12] [13] [14] In the 780 patients enrolled in CASS, 10 bypassed segments of native coronary artery were more likely to progress or occlude compared with nonbypassed segments, regardless of lesion severity, and the risk of progression increased with severity of stenosis at baseline (progression/occlusion rates 11% vs 4.3% for grafted vs ungrafted nondiseased segments, compared with 39% vs 19% for grafted vs ungrafted lesser lesions and 54% vs 28% for severe lesions). Likewise, in the Cholesterol Lowering Atherosclerosis Study, 14 native vessels proximal to a graft progressed more than those unrelated to bypass conduits. The overall disease progression in native coronary arteries was estimated at 10% at 2 years after surgery, as evaluated by quantitative coronary angiography, which seems in line with the progression rate of 27% noted in our data during longer duration of follow-up (mean, 6.2 years). Results in our data set are similar to that of the quoted literature [9] [10] [11] [12] [13] [14] : Bypassing a vessel increases its likelihood of new lesion development in previously undiseased vessels and increases its risk of disease progression in moderately stenosed vessels. It has been suggested that increased disease progression in bypassed vessels may be attributed to stasis of blood through the native coronary artery as a result of competition from a patent graft. 15 Our results also suggest that the excess of disease progression in bypassed vessels continues beyond the 2-year mark described in the Cholesterol Lowering Atherosclerosis Study, and that this occurs despite optimized modern secondary prevention agents with their numerous pharmacologic effects.
It is noteworthy that none of the series mentioned here reported the particular stability of ungrafted moderate right coronary lesions that we have found, perhaps because of the smaller number of ungrafted vessels or because of differences in study design. However, it is at least theoretically possible that this phenomenon has arisen more recently as a result of modern medical management, which might impact differently on lesions of different severity or different coronary sites, where patterns of coronary flow are not uniform. Nonetheless, it seems more likely that this preponderance of left-sided progression among moderate lesions is simply an extension of the greater prevalence of atherosclerotic disease in the left coronary circulation compared with the right coronary circulation, as has been reported in nonsurgical patients, 16, 17 which might arise from the anatomic and hemodynamic differences between the right and left coronary circulations. 18 In healthy nonbypassed vessels in our cohort (n ¼ 1650), the left circulation showed a greater tendency to develop de novo disease (7.7% vs 4.6%, P <.05), consistent with patterns of lesion distribution in other reports. 12, 13 Therefore, our data suggest that nonbypassed moderate lesions are behaving in a similar fashion to undiseased vessels, with a preponderance of left-sided progression and low risk of disease progression for the moderate right-sided lesion.
It is interesting that our data show right coronary vessels with>70% stenosis to exhibit a higher rate of disease progression than their left equivalents, suggesting perhaps a different natural history of advanced right coronary disease. In other words, although moderate right-sided lesions appear quite stable if left alone, severe lesions seem the opposite. This seems hard to explain, unless progression by atherosclerosis is linear on the left and exponential on the right, perhaps relating to differences in physiology and flow. This is speculative and has not been reported elsewhere. Direct comparisons with other studies present a challenge because of different study populations, methodology, and definitions of disease severity and progression. For example, within CASS, the definition of severe stenosis was !50% stenosis; therefore, the disease behavior of this group may, in fact, be a mixture of that of our moderately stenosed (40%-69%) and severely stenosed groups.
Limitations
There are number of limitations to this study that we acknowledge. The power of our analysis is limited by the number of patients who have, to date, undergone pre-and postoperative angiography (n ¼ 405). A larger sample size may have elicited other significant factors relevant to the PNVD. Although the recorded percent stenosis is the mean of several estimations by independent observers, a more accurate estimation of disease progression could be obtained by formal quantitative angiography. The addition of physiologic data from measurements of FFR would offer the gold standard of assessment of moderate lesions in current practice, but is not in widespread clinical use and has not been performed in this patient cohort.
Details of lesion topography (ulceration vs smooth contour, concentricity vs eccentricity, presence or absence of thrombus) is not recorded in our data set but may be relevant to clinical outcome and surgical decision making in some cases. Last, requirement for subsequent PCI or surgery is an incomplete marker for angina recurrence, but incomplete recording of ischemic symptoms in our clinical follow-up data did not allow safe correlation of these with angiographic progression, with which only revascularization events (as a surrogate for ischemia) could be compared.
CONCLUSIONS
Data from postoperative angiography in predominantly asymptomatic patients receiving contemporary secondary prevention therapies suggests that moderate lesions in the left coronary system are best treated by bypass grafting during multivessel revascularization, whereas right-sided lesions may reasonably be left alone because they are unlikely to progress and are not likely to require subsequent revascularization. These data may assist coronary surgeons in a common clinical dilemma.
Discussion
Dr Joseph F. Sabik (Cleveland, Ohio). Dr Smith, Dr Sundt, members, and guests, in this paper by Dr Hayward and colleagues, they address whether coronary arteries with moderate stenosis or nonischemia-producing lesions should be bypassed routinely during coronary artery bypass surgery. They conclude, as a result of the low rate of disease progression and low arterial graft patency, that it may be best not to bypass routinely right coronary arteries with moderate stenosis. They come to a very different conclusion for left-sided coronary arteries. Because the rate of disease progression is higher and the patency of arterial grafts performed to left-sided coronary arteries with moderate stenosis is excellent, they suggest that routinely bypassing left-sided coronary arteries with only moderate lesions may be appropriate.
This study is timely and important, especially in light of recent findings from the interventional study, FAME. In FAME, FFR-guided percutaneous coronary revascularization resulted in a 25% decrease in the combined end points of death, myocardial infarction, need for CABG, or repeat PCI. In other words, stenting moderate, or nonischemia-producing coronary artery stenosis, resulted in worse clinical outcomes. Might this also be true for routinely grafting coronary arteries with only moderate or nonischemia-producing lesions? I have 4 questions for Dr Hayward.
Although knowing how grafting influences coronary artery stenosis progression in moderate lesions is interesting and suggestive, to decide whether to graft coronary arteries with moderate stenosis requires clinical outcomes data. Did you follow the clinical events in these patients and, if you did, do you know if grafting moderate coronary artery lesions resulted in poorer long-term outcomes? Also, did it matter whether the grafted coronary with a moderate lesion was right or left sided? Second question: You observed different rates of lesion progression in the right and left coronary artery systems; moderately stenosed left-sided coronary arteries have a higher rate of disease progression than moderately stenosed right coronary arteries. Do you have an explanation for why disease progression is different for right-and left-sided coronary arteries?
Third question: Grafting a moderately stenosed coronary artery clearly resulted in greater lesion progression. Was the rate of lesion progression different whether an artery or saphenous vein was used as the bypass conduit?
And last, should we be using FFR guidance in determining which lesions should be bypassed during coronary artery bypass surgery? Thank you for the privilege of discussing this paper.
Dr Hayward. Thank you, Dr Sabik, for your comments and questions. I agree. I think that the data from FAME in interventional cardiology and another study, DEFER, which just looked at moderate lesions, which we can come back to, are very timely and in some ways can be extrapolated to this study.
To answer your 4 questions directly, if I have them correctly, clinical outcome data-I didn't include the clinical data in this because (1) we already had a lot of information (this was primarily intended as a study of angiographic progression) and (2) because these patients are part of the trial, we reported the mid-term results at AATS a couple of years ago and we are now awaiting the full 10-year completion data, and I have tried not to overtrawl the trial data too much, and the clinical outcome data of these patients might relate to the overall trial data, because we know the graft patencies and we know the progression of disease.
However, I can say that on the multivariate analysis, PNVD overall is not related to the incidence of death, myocardial infarction, or requirement for revascularization. The hazard ratio for all of those is in the range of .85 to .15 for those 3 end points. That's looking at all vessels. And if you look at moderate vessels, progression of moderate lesions is not associated on a multivariate analysis with the hazard ratio of death, infarction, or revascularization. What we haven't done, however, is divide those moderate vessels into grafted and ungrafted. The numbers are getting very small there.
So I cannot answer your question whether grafting a moderate lesion versus not grafting a moderate lesion will alter the end points that we have. We do not have recurrent angina as an end point in our trial, because the trial is limited to the very hard data points of death, infarction, and requirement for revascularization, so I cannot answer that question. But, I can say that those clinical end points are not related significantly to whether you have progressive or nonprogressive disease on your angiogram.
Dr Sabik. Why that might be is interesting, and as I read your paper I was wondering: Is this a competing risk problem? Moderate coronary lesions tend to be the culprit lesions, the lesions that acutely thrombose and result in myocardial infarctions. Might these patients be having events if these lesions are not grafted? I believe a good hard look at the clinical outcomes is necessary to determine whether to graft coronary arteries with moderate stenosis.
Dr Hayward. The second question that you asked is why should the progression of moderate right lesions be less than on the left, and I think that's obviously, if you like, the meaning of this paper. I don't have a hypothesis. I guess it may be that the pathophysiology of these is different. People have imputed the impact of lipids and the atherosclerotic burden and also of shear stresses, and in pathologic studies of autopsies and in, now, the coronary computed tomographic studies, we know that the burden of coronary disease is higher in the overall population in left-sided rather than right-sided vessels, and it has been postulated that's because left-sided vessels have more shear stresses being related to the left ventricle because they have a different flow pattern compared with the right coronary.
So it is possible, I guess, that the modern secondary prevention, particularly statins, both in their lipid modulatory and anti-inflammatory effects, may be exerting a different effect in the right coronary versus the left coronary, because they can modulate the lipid impact and the inflammatory impact-in other words, the atherosclerotic driver-but they can't alter the shear stresses, which are driven by the left ventricle essentially. That is the only reason I can think of why over 20 years, advances in medical therapy might have left us with these very stable right coronary lesions. Dr Sabik. I was wondering if this finding is a result of the way plaque burden was measured. Because increase in coronary stenosis is a result of increase in plaque thickness, by measuring percentage stenosis and not plaque thickness, I believe your findings may be a result of the differences in the different coronary artery diameters. A millimeter increase in plaque thickness will have a much greater effect on the percentage stenosis of circumflex with a 2-mm diameter then it would on a right coronary artery with a 5-mm diameter. To determine disease progression accurately, it may be necessary to determine changes in plaque size, not just percent stenosis.
Dr Hayward. That is a very good observation. We did not perform quantitative analysis, because to go back for 3800 vessels and perform quantitative analysis would be an enormous task, and we don't have funding for the team of people that would be needed to do that. But I think for these moderate lesions, particularly the ungrafted moderate lesions, the number is much smaller, and I think we should go back and do exactly that analysis-do quantitative analysis-to measure the burden of disease and find out whether this is, as you say, truly a stability effect of medical therapy or is it actually an artifact of a bigger vessel. It takes more burden to stenose a bigger vessel. I suspect the former is true, but we can measure that.
In terms of your third question, which was choice of conduit, there is no difference in the disease progression on multivariate analysis between whether you place an arterial or a vein graft, and that data will be in the manuscript with all the complete data. But, choice of conduit does not seem to impact on the rate of progression.
Your fourth question, I think, is whether the use of FFR should guide these studies, and I think that is the key point. Some of those moderate lesions are flow limiting; some of them are not. We know from the DEFER study, which was a study in interventional cardiology of 50% to 70% stenoses, and they performed FFR on those, only one-third of those lesions had an FFR of <0.75-in other words, were flow limiting-and the ones that weren't, they then randomized to stent or medical management. Not surprisingly, those patients who got medical management did significantly better than those who got a stent. And I think surgeons would recognize that if you put a stent in a vessel that is not actually flow limiting, that is going to impact on your long-term outcome, because it represents a lifetime risk for you.
We probably feel that the same is not true of bypass surgery, because if you put a bypass graft to a vessel and it wasn't actually flow limiting, well, the worst that can happen is the graft will fail and you haven't done any harm.
And I think what is interesting in our data is that may not be true, that the findings of FAME and DEFER might relate to surgery as well. Putting a bypass to a vessel that doesn't need it might be a bad thing, but if you accelerate the disease progression, especially as you probably put a vein graft to the right coronary-because you and other authors have documented the worst outcome of arterial grafts on moderate right lesions-if you are going to put a vein graft, you may accelerate the progression of the native disease, and that patient then becomes dependent on a graft on the right side, and that graft is going to have an attrition. So I think FFR to guide the actual revascularization of these lesions in the future will be the way to go. Dr Sabik. Thank you, and congratulations on an excellent presentation and paper.
